Council for Entrepreneurial Development (CED)’s Biotech Forum: Dealmaker's Intentions Survey
May. 19, 2010North Carolina Biotechnology Center
Raleigh, NC
www.cednc.org/content/biotech+forum/198
Description:
Campbell Alliance 2010 Dealmakers’ Intentions Survey
Gautam Aggarwal, Senior Practice Executive in our Business Development Practice, will present the results and observations from Campbell Alliance's 2010 Dealmakers' Intentions Survey and moderate a panel discussion with leading business development decision makers.
Abstract:
The relationship between the pharmaceutical and biotechnology industries has never been more apparent. For pharma, patent expiration and depleted pipelines have forced companies to look externally for growth. For biotech, the lack of financing and an uncertain regulatory and reimbursement landscape threatens the progress of innovative new therapies. In this environment, the competition for unlicensed assets has never been more intense and top dealmakers will shape the future of the industry.
Getting inside the heads of business development professionals is not an easy task. Many resources available to business development professionals provide retrospective data regarding deal activity in the pharmaceutical and biotech industry. These indispensable tools, including libraries of financing transactions, deal databases, and royalty rate studies, provide timely information on deal activity as transactions are closed and announced. However, because deals often take more than a year to complete, these databases may not be good indicators of emerging strategies or the future deal environment. CED, in partnership with Campbell Alliance, is pleased to offer the only forward-looking measure of deal-making intentions in the pharma and biotech industries. During the first quarter of this year, Campbell Alliance surveyed more than 150 industry executives and business development professionals on their partnering expectations and intentions for 2010. The study goes far deeper than simply evaluating the current environment to identify the types of assets that will be in demand among in-licensors. The results of this study have also been linked with a review of the assets that are available for licensing, revealing supply and demand dynamics that are not always obvious, and that could have interesting implications for deal-making over the next 12 months or more. In this competitive landscape, many biotech companies will need to effectively differentiate between certain assets’ intrinsic values, and the value that is simply driven by asset scarcity in certain categories. The study goes beyond evaluating these trends at the therapeutic area level, and includes assessments that incorporate popular or new mechanisms of action, target market segments, and so on. During this presentation and interactive panel discussion we will answer several key questions to provide insight into what will likely drive the industry’s partnering efforts moving forward.
Moderator:
Gautam Aggarwal, Senior Practice Executive, Business Development Practice, Campbell Alliance
Panelists:
Leslie Boyd, Vice President, Scientific Licensing, GlaxoSmithKline
Beth Fordham-Meier, CLP Vice President, Licensing and Intellectual Property, Targacept, Inc.
Kinney Horn, Associate Director, Business Development, Genentech
Joseph E. Zack, Senior Vice President, Diagnostics, Metabolon
Feature Articles
George Schmidt, Senior Vice President of the Sales Practice, discusses the impact of the current pharma and biotech landscape on sales forces and Training & Development departments....
Don't Miss
Campbell Alliance will exhibit at this event. Please visit us at booth # 5240. Also at the event, the Business Development Practice will be participating in partnering meetings in the Business Forum.
Webster Sun, Senior Practice Executive, Brand Management Practice, will moderate a panel discussion on the opportunities and challenges surrounding generic versions of many blockbuster biopharmaceutical products following their patent expiration.
Emily Hua, Vice President, Brand Management Practice, will moderate a panel discussion on first-to-market strategies and key lessons learned.
Kevin Barnett, Senior Vice President and Head of the Managed Markets Practice, Campbell Alliance and the Pharmaceutical Institute will participate in a panel discussion on health care reform and the potential implications for the life science industry.
George Schmidt, Senior Vice President, and John Bye, Vice President ,Sales Practice, will lead workshops on staying strategic in today's environment, driving sales force effectiveness and building sustainable training programs.
Campbell Alliance's Trade and Distribution Practice will exhibit at this event. Please visit us at booth #420.
Darius Naigamwalla, Senior Vice President and Global Practice Area Lead, and Tom Luginbill, Vice President, Brand Management Practice, lead a workshop on best practices for commercial planning and the requirements at each stage of the development process.
Keith Morris, Practice Executive, will present a session on successful communication strategies for effective execution of post-approval studies.
Joe Dillon, Senior Practice Executive, Campbell Alliance, will lead a discussion on maximizing the value of product candidates and technologies through a structured deal approach.
Kevin Barnett, Senior Vice President and Practice Area Lead, Managed Markets Practice will serve as chairman for the conference, as well as present a session on how to avoid common mistakes when contracting with payers.
Barrett Rankin, Practice Executive, Business Development Practice, will present a session on linking portfolio management with business development.
Executives from our Brand Management and Managed Markets Practice will have leadership roles at this event.
Kevin Barnett, Senior Vice President and Practice Area Lead, Managed Markets Practice, will present a session on developing and communicating a payer value proposition.
Campbell Alliance's Managed Markets Practice will exhibit at this event.
Campbell Alliance's Trade and Distribution Practice will exhibit at this event.
Executives from our Business Development Practice will moderate two panel discussions at this event.
Leaders from the Brand Management Practice will present a pre-conference workshop on strategies and best practices for managing the logistics of launch, while leaders from the Managed Markets Practice will present a health policy outlook for 2010.
Tony Lanzone, Vice President and head of the Trade and Distribution Practice at Campbell Alliance, will serve as conference chairman, while Jay Jauregui, also of the Trade and Distribution Practice, will present on developing a specialty distribution strategy.
Keith Kelly, Senior Practice Executive, Managed Markets Practice, will present a session on developing a managed care marketing strategy
Campbell Alliance is a sponsor of this event and executives within the Brand Management and Clinical Development Practices will attend.
Darius Naigamwalla, Senior Vice President and Global Practice Area Leader, Brand Management Practice, will present a session on systematically building commercial innovation into oncology launch plans. Also, Tony Lanzone, Vice President, Managed Markets Practice, will present a session on the evolving pricing, reimbursement, and access environment for oncology products.
Gary Tyson, Senior Vice President, Clinical Development Practice, will present a session on leveraging effective SOPs to create a community of compliance and adherence.
Gary Tyson, Senior Vice President, Clinical Development Practice, will present a session on the key learnings of CTMS implementation derived from the experiences of several organizations that have undergone implementation.
Three executives from our Business Development and Managed Markets Practices will present "Reimbursement: The New Investment Hurdle"
Darius Naigamwalla, Global Practice Area Leader, and Tom Luginbill, Vice President, both of the Brand Management Practice, will present a pre-conference workshop on strategies and best practices for strategically managing an oncology product launch. Also Tony Lanzone, Vice President in the Managed Markets Practice will moderate a payer panel discussion on the evolving pricing, reimbursement, and access environment for oncology products.
Mike Menta, Senior Practice Executive, Clinical Development Practice, will moderate a session on both opportunities and challenges of conducting clinical trials abroad.
Lujing Wang, Vice President, Managed Markets Practice, will present a session on evidence-based medicine in an evolving landscape for global market access.
Gautam Aggarwal, Senior Practice Executive in our Business Development Practice, will present the results and observations from Campbell Alliance's 2010 Dealmakers' Intentions Survey and moderate a panel discussion with leading business development decision makers.
Gautam Aggarwal, Senior Practice Executive, Business Development Practice, will present the results and observations from Campbell Alliance's Dealmaker's Intentions Survey.
Lujing Wang, a Vice President in our Managed Markets Practice, will present a session on "Evidence-Based Medicine in an Evolving Landscape for Global Market Access."
Christina Vitt, Associate Practice Executive, in our Clinical Development Practice, will present a session on "The Future of Oncology Clinical Development—Key Insights from Industry Experts on Trends and Future Direction."
Gautam Aggarwal, a Senior Practice Executive in our Business Development Practice, will present a session titled, "Less R, More D: How will Pharma Access Discovery in the Future?"
Ben Bonifant, Vice President and Head of the Business Development Practice, will moderate a panel discussion on "Reimbursement: The New Investment Hurdle."
Ben Bonifant, Vice President and Head of the Business Development Practice at Campbell Alliance, and Jim McCarthy, Senior Vice President, Corporate Development, Expression Genetics, will co-present the results of the "LES Global BioPharmaceutical Royalty Rates & Deal Terms Survey." Also at the event, Gautam Aggarwal, Senior Practice Executive in Campbell Alliance's Business Development Practice, will present a session on "When to Do the Deal: How to Know When the Time is Right."